Shenzhen Entrepreneur Day | Jingtai Technology Ma Jian: Combining the new paradigm of BT+IT Shenzhen has achieved differentiated development of the biomedical industry

Reading Chuang / Shenzhen Business Daily reporter Peng Yan Yuan Weibin

"By combining the new paradigm of BT+IT, Shenzhen's pharmaceutical industry can comprehensively use its geographical advantages and industrial bases such as the Internet, automation, and medical devices to differentiate itself from the biomedical industry clusters in the Yangtze River Delta and the Bohai Rim, and achieve a leading position in the field of biomedicine." Jintai Co-founder and CEO Ma Jian said.

Ma Jian said that in recent years, Shenzhen's biomedical industry has developed vigorously, the output value has developed rapidly at an average annual growth rate of 20%, and the added value of Shenzhen's biomedical industry will reach 40.825 billion yuan in 2020, and the biomedical industry will develop rapidly.

It is understood that Jingtai Technology is an artificial intelligence drug research and development company, committed to the automation and intelligence of drug research and development, rooted in Shenzhen, looking at the world, currently serving nearly 100 pharmaceutical customers worldwide. The company is registered in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone, and has R&D centers and business headquarters in Beijing and Shanghai.

Ma Jian said that the development of the biomedical industry, first of all, it is recommended that in terms of industrial layout, make full use of the advantages of Shenzhen's equipment and drug approval agency platform and the advantages of Research resources and talents in Hong Kong's international drugs, combine the advantages of technical reserves such as the Internet, artificial intelligence, and intelligent manufacturing to take a differentiated route, realize the empowerment of the whole process of medicine through AI, and realize the informatization, dataization, intelligence and platformization of the industrial chain.

At present, Shenzhen biomedicine has gathered a number of leading backbone enterprises such as Mindray Medical, Prudential Medical, BGI Gene, etc., and the biomedical industry has become an emerging industry in Shenzhen, but Shenzhen is facing a relative shortage of biomedical talents, the main line of the development of the biomedical industry is not clear enough, and the development of the biomedical industry between urban areas is not coordinated enough.

"To this end, the current electronic information industry in Shenzhen is highly developed, with leading software and hardware enterprises such as Huawei and Tencent, and very rich software and hardware resources, which is conducive to promoting the transformation and upgrading of the traditional pharmaceutical industry to BT+IT and other fields." Ma Jian said, "At the same time, Shenzhen enjoys the natural location advantage of the Guangdong-Hong Kong linkage, which is convenient for undertaking talents and funds from the Greater Bay Area." ”

Review: Sun Shijian